The Cancer Development and Progression (CDP) Program is one of three interactive research Programs of the Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center at San Antonio (UTHSCSA). The primary focus of the CDP Program is laboratory-based studies of fundamental problems in cancer etiology, but always with an eye towards translational potential. The major thematic areas in the CDP Program are (1) Genomic Integrity and Aging and (2) Hormones and Chronic Inflammation. The overarching scientific objectives of the CDP Program are to: (1) integrate basic and translational research in genomic integrity, age-related cancer susceptibility, hormone actions, and chronic inflammation to obtain a deeper and broader picture of cancer development and progression;(2) foster transdisciplinary, synergistic, and highly complementary collaboration between basic and translational research within the CDP Program and in the EDT and CPPS Programs;and (3) translate laboratory findings into novel approaches in cancer prevention and treatment. The CDP program is comprised of 31 members. Twenty-eight members represent eight departments within the School of Medicine at the UTHSCSA. Two members are from the University of Texas at Austin. The CDP Program members have $7,290,029 of peer-reviewed cancer-related funding (33 grants). Of those, $2,195,289 are from 10 NCI grants. Over the last funding period the CDP Program has 271 peer-reviewed cancer-related publications of which 26% are intra-programmatic collaborafions and 22% are inter-programmatic collaborations.
The Cancer Development and Progression (CDR) Program members perform cutting-edge laboratory-based cancer research to understand fundamental problems in cancer etiology with a continual focus on translational potential.
|Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93|
|Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :|
|Arora, Sukeshi Patel; Mahalingam, Devalingam (2018) Immunotherapy in colorectal cancer: for the select few or all? J Gastrointest Oncol 9:170-179|
|Arellano, Luisa M; Arora, Sukeshi Patel (2018) Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults. J Nat Sci 4:|
|Du, Liqin; Zhao, Zhenze; Suraokar, Milind et al. (2018) LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. Oncotarget 9:29601-29618|
|Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203|
|Sun, Xiujie; Gupta, Kshama; Wu, Bogang et al. (2018) Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulating adipose stromal interleukin 6 production in mice. J Biol Chem 293:2841-2849|
|Horning, Aaron M; Wang, Yao; Lin, Che-Kuang et al. (2018) Single-Cell RNA-seq Reveals a Subpopulation of Prostate Cancer Cells with Enhanced Cell-Cycle-Related Transcription and Attenuated Androgen Response. Cancer Res 78:853-864|
|Gong, Siqi; Tomusange, Khamis; Kulkarni, Viraj et al. (2018) Anti-HIV IgM protects against mucosal SHIV transmission. AIDS 32:F5-F13|
|Gelfond, Jonathan; Goros, Martin; Hernandez, Brian et al. (2018) A System for an Accountable Data Analysis Process in R. R J 10:6-21|
Showing the most recent 10 out of 989 publications